Substance / Medication

Valganciclovir

Overview

Active Ingredient
valganciclovir
RxNorm CUI
275891

Indications

N/A

Labeler: Somerset Therapeutics, LLCUpdated: 2026-01-22T00:00:00.000ZFull label on DailyMed

Boxed Warning

FDA Black Box Warning

[see Warnings and Precautions (5.1)] . • Hematologic Toxicity: Severe leukopenia, neutropenia, anemia, thrombocytopenia, pancytopenia, and bone marrow failure including aplastic anemia have been reported in patients treated with valganciclovir [see Warnings and Precautions (5.3)] . [see Warnings and

Contraindications

When this intervention should not be used

[see Adverse Reactions (6.1)] . Valganciclovir hydrochloride is contraindicated in patients who have had a demonstrated clinically significant hypersensitivity reaction (e.g., anaphylaxis) to valganciclovir, ganciclovir, or any component of the formulation

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Intrauterine therapy of cytomegalovirus infection with valganciclovir: review of the literature.
Seidel Vera, Feiterna-Sperling Cornelia, Siedentopf Jan-Peter et al. · Med Microbiol Immunol · 2017
PMID: 28733760Meta-Analysis
[Clinical efficacy and safety of prolonged use of the valganciclovir for the treatment of cytomegalovirus disease in patients after kidney transplantation].
Kawalec Paweł, Szkultecka-Debek Monika, Maks Justyna et al. · Pol Merkur Lekarski · 2013
PMID: 23984598Meta-Analysis
Risk of cytomegalovirus disease in high-risk liver transplant recipients on valganciclovir prophylaxis: a systematic review and meta-analysis.
Kalil Andre C, Mindru Cezarina, Botha Jean F et al. · Liver Transpl · 2012
PMID: 22887929Meta-Analysis
Valganciclovir for cytomegalovirus prevention in solid organ transplant patients: an evidence-based reassessment of safety and efficacy.
Kalil Andre C, Freifeld Alison G, Lyden Elizabeth R et al. · PLoS One · 2009
PMID: 19436751Meta-AnalysisFull text (PMC)
Prevention of posttransplant cytomegalovirus disease and related outcomes with valganciclovir: a systematic review.
Sun H-Y, Wagener M M, Singh N · Am J Transplant · 2008
PMID: 18828771Meta-Analysis
Valganciclovir: an advance in cytomegalovirus therapeutics.
Cocohoba Jennifer M, McNicholl Ian R · Ann Pharmacother · 2002
PMID: 12022911Meta-Analysis

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Valganciclovir (substance)
SNOMED CT
129476000
UMLS CUI
C0909381
RxNorm CUI
275891
Labeler
Somerset Therapeutics, LLC

Clinical Data

This intervention maps to 2 entities in the Ltrl knowledge graph.

2
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.